A Randomized Phase II Trial of Combination Anastrozole (NSC 719344) Plus ZD1839 (Iressa, NSC 715055, IND 61187) and of Combination Fulvestrant (NSC 719276) Plus ZD1839 in the Treatment of Postmenopausal Women With Hormone Receptor-Positive Metastatic Breast Cancer

Trial Profile

A Randomized Phase II Trial of Combination Anastrozole (NSC 719344) Plus ZD1839 (Iressa, NSC 715055, IND 61187) and of Combination Fulvestrant (NSC 719276) Plus ZD1839 in the Treatment of Postmenopausal Women With Hormone Receptor-Positive Metastatic Breast Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Dec 2015

At a glance

  • Drugs Anastrozole (Primary) ; Fulvestrant (Primary) ; Gefitinib (Primary)
  • Indications Advanced breast cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 01 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Apr 2011 Planned End Date changed from 1 Sep 2005 to 1 May 2011.
    • 04 Jun 2009 Results presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top